Like Toyota, Nissan to expand U.S. production to avoid North American tariffs under USMCA

TOKYO — Nissan Motor will start producing engines for a luxury crossover SUV in the U.S. to avoid tariffs under a reworked North American trade agreement (USCMA)  that requires 75% of a car’s parts to be locally sourced Read more

U.S.-Japan trade talks delayed by push for China deal

Agricultural products, including dairy, are expected to be one of the main topics in a Japan-U.S. bilateral trade agreement.

TOKYO — Japan and the U.S. are struggling to lay out a timeline for negotiations toward a bilateral trade agreement as Washington focuses its energies on securing a deal with Beijing. The first meeting will likely not come until at least early May Read more

U.S. Trade Policy Agenda in 2019 – USMCA and China

The USTR Annual Report says a successful 2019 will involve getting USMCA approved by Congress and reaching a deal with China that satisfies U.S. complaints. Japan, the EU, and UK are next in line. Read more

Trump opens door to TPP return

DAVOS, Switzerland — U.S. President Donald Trump on Thursday said he would rejoin the Trans-Pacific Partnership trade deal, which he decided to exit back in January 2017, if “we made a much better deal than we had.”

The 11 remaining TPP members just Tuesday set a date for signing a revised version of the deal. Trump had previously refused to rejoin the trade pact despite repeated calls by Japanese Prime Minister Shinzo Abe, choosing instead to focus on bilateral agreements. But he appears to have changed tack amid pressure from U.S. business leaders. Read more

U.S. WTO Brief Rejects China’s Bid for ‘Market Economy’ Status

WASHINGTON—The Trump administration has formally rejected China’s demand that it be treated as a “market economy” under global trading rules, a move likely to heighten tensions between the world’s two largest economies.

Read more

U.S. reaffirms China’s Non-Market Economy (NME) Status in antidumping case

Recently, the U.S. administration reaffirmed China’s non-market economy (NME) status for antidumping purposes.

The U.S. Commerce Department has instructed Customs and Border Protection to collect cash deposits from U.S. importers of Chinese-made aluminum foil at dumping margins ranging from 96.81 percent to 162.24 percent. Read more

Prime Minister Phuc’s Official Visit to Washington

There have been recurrent rumors that Hanoi and Washington might agree to explore a bilateral trade pact that would entail many TPP-like trade reforms. To the extent that’s true (official confirmation is lacking on both sides), jump-starting bilateral trade talks will be at the top of Prime Minister Nguyen Xuan Phuc’s agenda when he visits Washington this week. Read more

USTR Lighthizer at APEC Trade Ministers’ Meeting in Hanoi: “I’m here.”

Was the terse response from U.S. President Donald Trump’s new  trade representative, signalling perhaps some commitment to the Asia-Pacific, when CNBC asked him what message he hoped to convey to trade ministers gathered at an APEC meeting in Hanoi, Vietnam. Read more

Japan to support 11-nation TPP at May APEC Ministers Meetings in Hanoi

Trade ministers from 11 countries which agreed to join the Trans Pacific Partnership (TPP) will meet in Hanoi May 19 – 20, as moves to resurrect the trade deal gather pace.  Japanese Prime Minister Shinzo Abe warned in November 2016 that without the world’s largest economy the TPP “has no meaning”. But Japan’s position appears to have changed. On Thursday Deputy Prime Minister Taro Aso gave a speech in New York confirming trade ministers from the other TPP countries would meet in May to discuss the deal, which he said offered more than bilateral trade negotiations.  Read more

Does U.S. medical research subsidize other countries?

The U.S. is the world leader in producing new medicines. The country’s strong intellectual-property laws, coupled with a comparatively free-market pricing system, encourage firms to research new treatments. Companies wouldn’t take on the enormous cost of developing a new drug without a solid chance of recouping their investment. On average, a new medicine takes 10 years and costs $2.6 billion to develop, according to the Tufts Center for the Study of Drug Development.

The problem is that rather than promote innovation, many other countries impose price controls on prescription drugs—including new medicines invented in the United States—to make them artificially cheaper for consumers. If American companies refuse to sell their medicines at these steeply discounted dictated prices, foreign countries threaten to break their patents and produce knockoff versions of the medicines. Read more